Difficulty: Medium
Average Score: 73%
Practice
You are evaluating a 6-mo-old girl with a firm right suprarenal mass. Histologically, there is no bony involvement, 10% bone marrow involvement, subcutaneous nodules involvement, and massive abdominal mass. The N-myc oncogene is not amplified. According to the international neuroblastoma staging system, the infant is stratified as
Correct answer
D
Rationale
In this case, the correct answer is D) stage IV S. This is because the scenario describes a 6-month-old girl with a neuroblastoma tumor that has already metastasized extensively, with involvement in the bone marrow, subcutaneous tissue, and a massive abdominal mass. The absence of N-myc amplification suggests a more favorable prognosis than if N-myc were amplified.
Option A) stage I is incorrect because there is already metastasis present in this case. Option B) stage II A is also incorrect as the tumor has spread beyond the primary site. Option C) stage III is not the correct choice because of the extensive metastasis described in the scenario.
Educationally, understanding the staging of neuroblastoma is crucial for pediatric practitioners as it guides treatment decisions and prognostication. This case highlights the importance of recognizing the extent of disease spread in neuroblastoma cases and how specific genetic markers can influence prognosis and treatment strategies. This knowledge is essential for providing optimal care to pediatric patients with neuroblastoma.
Option A) stage I is incorrect because there is already metastasis present in this case. Option B) stage II A is also incorrect as the tumor has spread beyond the primary site. Option C) stage III is not the correct choice because of the extensive metastasis described in the scenario.
Educationally, understanding the staging of neuroblastoma is crucial for pediatric practitioners as it guides treatment decisions and prognostication. This case highlights the importance of recognizing the extent of disease spread in neuroblastoma cases and how specific genetic markers can influence prognosis and treatment strategies. This knowledge is essential for providing optimal care to pediatric patients with neuroblastoma.